This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) operates in a peptide sector undergoing a significant regulatory shift following the publication of a new federal policy permitting licensed pharmacies and physicians to compound six previously restricted peptides under specified conditions. According to an Oct. 28 Reuters report by Sneha S K, with additional reporting by Kamal Choudhury and Siddhi Mahatole, the policy, published in the Federal Register, allows compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax without Food and Drug Administration (“FDA”) enforcement action, provided compounders meet requirements for ingredient quality, manufacturing standards, safety reporting, labeling and patient-specific prescriptions. The measure represents a concrete regulatory development for the peptide industry, with analysts estimating the market could reach $2 billion to $3 billion if legitimized.
The interim policy follows a July FDA advisory committee recommendation to permit compounding of the six peptides, despite agency scientists raising concerns about insufficient safety and effectiveness data. Health and Human Services officials said the approach could reduce reliance on potentially unsafe research-use-only peptides imported from foreign manufacturers while improving patient access. Industry representatives welcomed the decision, although critics warned of potential contamination, impurities and unknown side effects. The policy does not constitute FDA approval of the peptides and could be reconsidered if safety or quality concerns emerge. The regulatory development adds a new dimension to the evolving market environment for peptide-focused companies, including Adaptogenics Health. The Reuters report was edited by Shilpi Majumdar, Maju Samuel, Vijay Kishore, Caroline Humer and Leroy Leo.
About Adaptogenics Health Corp.
Adaptogenics Health Corp. is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The Company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The Company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN